Method and Composition of Less Immunogenic, Long- Circulating Protein- Lipid Complexes

These novel compositions provide for enhanced delivery of protein therapeutics. Proteins (e.g. recombinant or full-length Factor VIII) associated with LIPRO-FORM (see R-6031 as well) exhibited markedly improved pharmacokinetic profiles and higher e fficacies in animal models. With characteristics such as lowered immunogenicity and increased circulation time, LIPRO-FORM provides significant potential advantages including a reduction in the frequency of administration, an abatement of inhibitor development and an extension of patent life.

Categories: Therapeutic and Vaccines

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---